Bring the immune system one step Ahead of cancer
An allogeneic platform designed to generate first in class immune therapy with the goal of harnessing the patient immune system and preventing resistance to cancer treatment.
0%
of patients currently undergoing
treatment for solid tumors will experience treatment failure.
Our mission at Brenus is to provide a solution to cold solid tumors – today’s biggest, unmet need in oncology.
Cancer = A moving target
The efficacy of current approaches is compromised by drug resistance within the tumor, which is a scalable process. The cell population constantly shifts during therapy, causing cancer to be considered a ‘moving target’.
Our technology leverages three major principles, in a single solution. To harness a specific, highly potent and lasting immune response
STC platform
Representativity
Strict and AI assisted selection of specific allogeneic tumor cell lines provides those most representative of the targeted indication.
Representativity
The scalable and unique STC Platform is an allogeneic technology which mimics and represents the cellular heterogeneity of the patient’s tumor. REPRESENTATIVITY (diversity) is ensured by cell lines selected from a data base and with in vitro tests (cold tumor, hot tumor, oncogenic drivers : TP53, BRAF, KRAS,….).
Antigenicity
STC technology educates the immune system with the widest range of neo-antigens of interest.
Antigenicity
Our technology prepares and trains the representative cells of interest: Firstly, through physical exposure (low radiation – heat shock) and secondly, with chemical treatment (clinical cytotoxic molecules). The ANTIGENICITY (plasticity) of our solution is ensured by more than 200 neo-antigens expressed on the cell surface. The neo-antigens are TAA (Tumor Associated Antigens) – TSA (Tumor Specific Antigens) which constitute the largest range of resistance factors.
Immunogenicity
A haptenization process educates a patient’s immune system to recognize and turn target protein visible, producing a more potent immune response.
Immunogenicity
In a very innovative way, and to ensure the IMMUNOGENICITY of our solution, a recognition tag associated with surface neo-antigens is added by haptenization. This step makes the solution, which is already representative and antigenic, visible to the patient’s immune system, and therefore very immunogenic.
B. PinteurFounder & Chief Scientific Officer
P. BravettiManaging Director
A.BordetCFO (Part time)
L.Chalus Lead Technical Operations
C. TORTORELLI Senior Lead Medical Affairs
L.PerlesLead Strategic Marketing & External Opportunities
M.BRUNProject Manager, External communication
G.AlzeebScientific Project Manager
Dr F. GhiringhelliHead of Scientific Board
CGFL, Dijon (FR)
Dr I.MelereoCIMA Universidad de Navarra (SP)
Pr A. ItalianoInstitut Bergonié, Bordeaux
Intsitut Gustave Roussy,
Paris (FR)
Highly skilled executive backed by top academic experts and a science backed by world class scientific leaders.
Team